These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 6812366

  • 1. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E, Bianco I, Graziani B, Lerone M, Valente M, Congedo P, Ponzini D, Costantini S.
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [Abstract] [Full Text] [Related]

  • 2. Chelation therapy in beta-thalassemia major. III. The role of splenectomy in achieving iron balance.
    Graziano JH, Piomelli S, Hilgartner M, Giardina P, Karpatkin M, Andrew M, LoIacono N, Seaman C.
    J Pediatr; 1981 Nov; 99(5):695-9. PubMed ID: 7299540
    [Abstract] [Full Text] [Related]

  • 3. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A, Mizanin J, Schwartz E.
    Prog Clin Biol Res; 1989 Nov; 309():125-31. PubMed ID: 2780746
    [No Abstract] [Full Text] [Related]

  • 4. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS, Sanchis de Herrlein MS, Peñalver JA.
    Medicina (B Aires); 1985 Nov; 45(3):231-4. PubMed ID: 3841934
    [No Abstract] [Full Text] [Related]

  • 5. [Monitoring and appraisal of the effects of blood transfusion and iron chelation in thalassemia major].
    Girot R, Triadou P, Bories D, Jeannel F, Thevenin M, Rymer JC.
    Nouv Rev Fr Hematol (1978); 1982 Nov; 24(5):281-7. PubMed ID: 7167380
    [Abstract] [Full Text] [Related]

  • 6. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 7. A study of the mechanisms and sites of action of desferrioxamine in thalassaemia major.
    Bianco I, Graziani B, Lerone M, Congedo P, Clemente GF, Ingrao G, Ciccone F, Di Nucci GD, Mandelli F, Isacchi G.
    Acta Haematol; 1984 Jun; 71(2):100-5. PubMed ID: 6421046
    [Abstract] [Full Text] [Related]

  • 8. Long-term effect of splenectomy on transfusion requirements in thalassemia major.
    Cohen A, Gayer R, Mizanin J.
    Am J Hematol; 1989 Apr; 30(4):254-6. PubMed ID: 2929586
    [Abstract] [Full Text] [Related]

  • 9. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 10. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C, Youssry I, Sobh H, Hamdy M, Sharaf I, Mostafa A, Shaker O, Hoffbrand AV, Taher A.
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [Abstract] [Full Text] [Related]

  • 11. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S, Cossu P, Sanna G, Frau F, Loi E, Lobrano R, Nucaro A, Toccafondi C, Cornacchia G, Loi A, Cao A.
    Acta Haematol; 1982 Jul; 67(1):49-56. PubMed ID: 6800202
    [Abstract] [Full Text] [Related]

  • 12. Urinary iron excretion induced by intravenous infusion of deferoxamine in beta-thalassemia homozygous patients.
    Boturao-Neto E, Marcopito LF, Zago MA.
    Braz J Med Biol Res; 2002 Nov; 35(11):1319-28. PubMed ID: 12426631
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R, Thévenin M, Bouveret JP, Jeannel F, Rymer JC.
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [Abstract] [Full Text] [Related]

  • 14. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Apr; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 15. Advances in the use of iron-chelating agents for the treatment of iron overload.
    Modell B.
    Prog Hematol; 1979 Apr; 11():267-312. PubMed ID: 392593
    [No Abstract] [Full Text] [Related]

  • 16. Clinical management of beta-thalassemia.
    Graziano J, Piomelli S.
    Tex Rep Biol Med; 1979 Apr; 40():355-64. PubMed ID: 7034276
    [No Abstract] [Full Text] [Related]

  • 17. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children.
    Gomber S, Saxena R, Madan N.
    Indian Pediatr; 2004 Jan; 41(1):21-7. PubMed ID: 14767084
    [Abstract] [Full Text] [Related]

  • 18. [Effect of desferal therapy on indices of iron metabolism in patients with intermediate forms of beta-thalassemia].
    Efendieva EG, Dashkova NG.
    Gematol Transfuziol; 1987 Sep; 32(9):23-6. PubMed ID: 3692120
    [No Abstract] [Full Text] [Related]

  • 19. Reduction of iron overload in thalassemia.
    Piomelli S, Graziano J.
    Birth Defects Orig Artic Ser; 1982 Sep; 18(7):339-46. PubMed ID: 7159742
    [No Abstract] [Full Text] [Related]

  • 20. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Sep; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.